Cullinan Therapeutics has completed and submitted to the FDA an NDA for zipalertinib plus platinum-based chemotherapy for previously untreated locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Source:CancerNetwork · Read original
Leave a Reply